DexCom, Inc. (DXCM)

NMS – Real Time Price. Currency in USD

70.14

+1.49 (2.17%)

At close: Jun 26, 2026, 4:00 PM EDT

69.95

-0.19 (-0.27%)

After-hours: Jun 26, 2026, 7:57 PM EDT

16.06.2026

DXCM Receives FDA Clearance for Stelo OTC CGM System for Children

DexCom's FDA-cleared Stelo OTC glucose biosensor now covers children aged above 2 years not using insulin, expanding access to smartphone-linked CGM insights.

16.06.2026

Here's Why DexCom (DXCM) is a Strong Growth Stock

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

12.06.2026

FDA clears first over-the-counter glucose monitor for children

The U.S. Food and Drug Administration said on Friday it has expanded the use of Dexcom's Stelo Glucose Biosensor ‌System to children with diabetes, making it the first over-the-counter continuous glucose monitor for pediatric use.

11.06.2026

Pharmsource says it was unaware Dexcom sensors it bought were slated for destruction

Drug wholesaler Pharmsource LLC said it was unaware the Dexcom glucose sensors it bought from licensed distributors had been ‌slated for destruction, after the device maker warned some units were stolen during disposal and resold.

10.06.2026

Why DexCom (DXCM) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

08.06.2026

DexCom Reports Positive CONNECT Data for Non-Insulin Diabetes

DXCM reports positive CONNECT trial results as Dexcom G7 improves HbA1c and time in range in adults with Type 2 diabetes not using insulin.

08.06.2026

Clinical Wins Boost Dexcom Growth Story In Type 2 Diabetes

DexCom Inc. (NASDAQ:DXCM) stock is trading higher on Monday after the diabetes management company reported positive results from its CONNECT randomized controlled trial.

Videos

19.02.2026

Positive

The Big 3: VZ, DXCM, AMAT

13.01.2026

Neutral

Watch CNBC's exclusive interview with Dexcom CEO Jake Leach

05.08.2025

Positive

Dexcom's Arizona facility can service good portion of U.S. business, says CEO

Upgrades / Downgrades

Ticker	Brokerage Firm	Ratings Change	Price Target	Date
DXCM	Evercore ISI	In-line	undefined >> $68	November 25th 2025
DXCM	Stifel	Buy	undefined >> $85	October 21st 2025
DXCM	Oppenheimer	Perform	undefined >> undefined	September 8th 2025
DXCM	Argus	Buy	undefined >> $100	August 21st 2025
DXCM	Truist	Buy	undefined >> $102	June 16th 2025
DXCM	Goldman	Buy	undefined >> $104	May 30th 2025

Press releases

06.06.2026

Dexcom CONNECT Study: The Most Significant Clinical Study Demonstrating CGM Benefits for People with Type 2 Diabetes Not Using Insulin

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) announced today results from the CONNECT randomized controlled trial, demonstrating the use of Dexcom G7 leads to clinically and statistically significant reduction in A1C and improvement in glucose control among people with Type 2 diabetes not using insulin compared with a routine care control group using self-monitoring of blood glucose.1 Researchers presented these results today as an oral presentation at the 2026 Scientific Sessions of.

04.06.2026

Dexcom Reaffirms CGM Benefits for All People With Diabetes and Continues Momentum Toward Earlier Stage Intervention and Preventative Care at ADA 2026

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM) will present new clinical findings, product advancements and strategic business initiatives reinforcing its commitment to improving care for people with all types of diabetes and ushering in a new era of early stage CGM intervention and preventative care at the American Diabetes Association's Scientific Sessions in New Orleans, June 5-8, 2026. “Dexcom has built a legacy of innovation within the diabetes space and as we look to the future, e.

02.06.2026

Dexcom Releases Customer Advisory Council Report, Outlining Ongoing Commitments to Enhancing Product Performance and User Experience

SAN DIEGO--(BUSINESS WIRE)--Dexcom, Inc., the global leader in glucose biosensing, today released its inaugural Customer Advisory Council Report, detailing candid feedback from users, caregivers, healthcare professionals and community leaders, along with clear, actionable company commitments to further elevate product performance and user experience. Building on its position as the manufacturer of the most accurate CGM systems1, Dexcom continues to listen, innovate and act on customer insights.

26.05.2026

Dexcom Uncovers Theft of Scrapped Product, Notifies Potentially Impacted Users

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (Nasdaq: DXCM), the global leader in glucose biosensing, announced today through ongoing quality and accounting reviews it recently identified certain lots of Dexcom G7 sensors originally designated as scrap and intended for destruction were stolen during the destruction process, then sold by third parties. Scrapping limited amounts of sensors that do not meet Dexcom standards is a routine part of the company's quality control process. Sensors identified.

DexCom, Inc. (DXCM)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

DexCom, Inc. (DXCM)

DXCM Receives FDA Clearance for Stelo OTC CGM System for Children

Here's Why DexCom (DXCM) is a Strong Growth Stock

FDA clears first over-the-counter glucose monitor for children

Pharmsource says it was unaware Dexcom sensors it bought were slated for destruction

Why DexCom (DXCM) is a Top Momentum Stock for the Long-Term

DexCom Reports Positive CONNECT Data for Non-Insulin Diabetes